Levetiracetam
Product Images NDC 55488-0519

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55488-0519). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Changzhou Pharmaceutical Factory, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container Label (Container Label)

Label for LEVETIRACETAM Extended-Release Tablets USP 750 mg manufactured by Changzhou Pharmaceutical Factory. The label indicates a package of 60 tablets with once daily dosing. The label also includes storage instructions and a barcode, with the product distributed by Overseas Pharmaceuticals LLC.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing the percentage of patients in three groups: Placebo (7.4%), Immediate-release Levetiracetam 1000 mg/day (37.1%), and Immediate-release Levetiracetam 3000 mg/day (39.6%). Each bar represents the proportion of patients responding within each treatment group.*

FDA Label Image

Figure2 (Figure2)

A bar chart showing the percentage of CPR positive responses for three groups: Placebo, Immediate-release Levetiracetam 2000mg/day, and Immediate-release Levetiracetam 1000mg/day. The percentages are labeled above each bar, indicating response differences among the groups.*

FDA Label Image

Figure3 (Figure3)

A bar graph comparing the percentage of patients between placebo and Immediate-release Levetiracetam 3000 mg/day groups. The y-axis represents the percentage of patients from 0% to 45%. The placebo group (N=104) shows 14.4%, while the Levetiracetam group (N=180) shows 39.4%, with an asterisk indicating statistical significance.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients responding to placebo versus immediate-release levetiracetam. The placebo group (N=97) shows a 19.6% response rate, while the immediate-release levetiracetam group (N=101) shows a 44.6% response rate. The y-axis represents the percentage of patients.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of levetiracetam, the active ingredient in LEVETIRACETAM Extended-release by Changzhou Pharmaceutical Factory. The structure depicts the molecular configuration including the pyrrolidone ring and side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.